Jill Andersen Biography and Net Worth

Chief Legal Officer & Corporate Secretary of Invivyd

Jill Andersen, J.D. has served as our Chief Legal Officer and Corporate Secretary since November 2021. She has worked extensively on matters related to product development, marketing approval, and commercialization, including product launches across multiple therapeutic areas. Her experience also spans corporate governance, securities, corporate transactions, IP, litigation, and investigations. Jill has spent over 15 years in the pharmaceutical and biotechnology industries, most recently at Oyster Point Pharma where she served as General Counsel, Corporate Secretary and Chief Compliance Officer from June 2020 to October 2021. Before joining Oyster Point, Ms. Andersen served as Vice President and Head of Legal, Inflammation & Immunology Franchise at Celgene Corporation from September 2016 to November 2019 until the acquisition by Bristol-Myers Squibb Company where she served as Vice President, Legal from November 2019 to May 2020. Prior to Celgene, Ms. Andersen held senior legal leadership roles of increasing responsibility within the Novartis companies from 2007-2016. Before joining the pharmaceuticals industry, Ms. Andersen served as an Assistant United States Attorney for the District of New Jersey. She holds a J.D. from Wake Forest University and a B.S. in Finance from Boston College.

What is Jill Andersen's net worth?: The estimated net worth of Jill Andersen is at least $311.68 thousand as of February 18th, 2026. Ms. Andersen owns 181,736 shares of Invivyd stock worth more than $311,677 as of April 10th. This net worth estimate does not reflect any other assets that Ms. Andersen may own. Learn More about Jill Andersen's net worth.
How do I contact Jill Andersen?: The corporate mailing address for Ms. Andersen and other Invivyd executives is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. Invivyd can also be reached via phone at 781-819-0080 and via email at [email protected]. Learn More on Jill Andersen's contact information.
Has Jill Andersen been buying or selling shares of Invivyd?: Jill Andersen has not been actively trading shares of Invivyd over the course of the past ninety days. Most recently, Jill Andersen sold 34,939 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a transaction totalling $55,203.62. Following the completion of the sale, the insider now directly owns 181,736 shares of the company's stock, valued at $287,142.88. Learn More on Jill Andersen's trading history.
Who are Invivyd's active insiders?: Invivyd's insider roster includes Robert Allen, III (Chief Scientific Officer), Jill Andersen (Chief Legal Officer & Corporate Secretary), William Duke (Chief Financial Officer), Julie Green (Chief Human Resources Officer), Timothy Lee (Chief Commercial Officer), and Terrance McGuire (Director). Learn More on Invivyd's active insiders.
Are insiders buying or selling shares of Invivyd?: In the last twelve months, Invivyd insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $125,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 504,826 shares worth more than $521,748.82. The most recent insider tranaction occured on February, 18th when insider Robert D Allen III sold 19,392 shares worth more than $30,639.36. Insiders at Invivyd own 25.4% of the company. Learn More about insider trades at Invivyd.
Information on this page was last updated on 2/18/2026.

Jill Andersen Insider Trading History at Invivyd

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2026	Sell	34,939	$1.58	$55,203.62	181,736
2/17/2026	Sell	32,771	$1.54	$50,467.34	216,675
8/19/2025	Sell	49,402	$0.57	$28,159.14	84,446
8/18/2025	Sell	33,352	$0.65	$21,678.80	133,848

Jill Andersen Buying and Selling Activity at Invivyd

Invivyd Company Overview

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $1.77

$1.62

$1.77

50 Day Range

MA: $1.59

$1.19

$1.90

2 Week Range

Now: $1.77

$0.46

$3.07

Volume

8,779,937 shs

Average Volume

3,074,031 shs

Market Capitalization

$499.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73